Drug Profile
Research programme: multiple sclerosis therapies - Vivoryon Therapeutics/Synt:em
Alternative Names: Syn-5001Latest Information Update: 17 Jun 2019
Price :
$50
*
At a glance
- Originator Probiodrug; Synt:em
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 11 Jun 2019 Probiodrug is now called Vivoryon Therapeutics
- 11 Jul 2003 Preclinical trials in Multiple sclerosis in France (unspecified route)